Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Clearpoint Neuro, Inc. (CLPT)
A forensic read on Clearpoint Neuro, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Grey Zone
Financial health
1.5
Distress distance
Watch
Earnings quality
5
Forensic signals
-12.0
P / E (ttm)
-91.1%
ROE
$455M
Market cap
0.00%
Dividend yield
17.8%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Clearpoint Neuro, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 1.5, placing it in the Grey zone. 5 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+142.0%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +142.0% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The build is led by receivables up +39% against revenue +18% and inventory up +22% against +16% in cost of sales. The cash-flow cross-check is more mixed: reported earnings ran behind operating cash by 9% of net operating assets, diverging from the balance-sheet accrual read.
-46.5%
FY2025
Return on invested capital.Return on invested capital is -46.5% in the latest fiscal year and rising from -61% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+5.4%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +17% over the last 3 years to FY2025 (+5.4%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~5.4% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~15%.
56d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 46 to 56 days FY2024→FY2025 (receivables +39% vs revenue +18%). Receivables are creeping up relative to sales. Across FY2021–FY2025 the day count ran 47 → 44 → 45 → 46 → 56 days, so the latest reading sits on top of a record that was flat or falling before it — one year's move, not a direction the business has been travelling in. Deferred revenue was roughly flat (-12%) over the same period, which doesn't corroborate a benign upfront-billing explanation for the receivables build. Measured against the same quarter twelve months earlier — like-for-like on the calendar, so an ordinary seasonal build cannot produce it — receivables took longer to collect in 3 consecutive quarters (Dec 2025 +2, Mar 2026 +26, Jun 2026 +28 days). In the latest of them the receivable balance grew +97% against sales +18%, so more of a quarter's billings were still outstanding at the period end than a year earlier — money the company has recognized and not yet been paid.
Key fundamentals
Latest Revenue$37.0M
Revenue Growth YoY+17.8%
Revenue CAGR (3yr)+21.6%
Net Margin-69.1%
Free Cash Flow-$24.4M
Return on Equity-91.1%
Debt / Equity1.75x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Clearpoint Neuro, Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.
22% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 22% of revenue in FY2025 — about $0.29 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count, and there it has run at about 5.5% a year and is falling.
Clearpoint Neuro, Inc. (CLPT) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy